Michael Smylie
University of Siena
3 papers in the Anchorcite directory, published between 2005 and 2017, cited 19,238 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 2 papers
- Cutaneous Melanoma Detection and Management · 2 papers
- Melanoma and MAPK Pathways · 2 papers
- Lung Cancer Diagnosis and Treatment · 1 paper
- Lung Cancer Treatments and Mutations · 1 paper
- Lung Cancer Research Studies · 1 paper
Frequent co-authors
- James Larkin · 2 papers
- Vanna Chiarion‐Sileni · 2 papers
- Rene C. Gonzalez · 2 papers
- Jean‐Jacques Grob · 2 papers
- Charles Lance Cowey · 2 papers
- Christopher D. Lao · 2 papers
- Dirk Schadendorf · 2 papers
- Reinhard Dummer · 2 papers
Papers
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine · 2015 · 8,341 citations
BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab…
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine · 2005 · 5,451 citations
BACKGROUND: We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy. METHODS: Patients with stage IIIB or IV non-small-cell…
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2017 · 5,446 citations
BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS:…
Metadata from OpenAlex (CC0).